PhytaGenics Inc.

01 May 2001

• By Mark Ratner

PhytaGenics is using transgenic technology to produce high-value pharmaceutical proteins and bulk enzymes in the leaves of potato plants as well as other species, under greenhouse conditions.

Their nutritious, compact tubers may make potatoes a sought-after foodstuff, but to PhytaGenics Inc. , the vines are where the action is. The company is using transgenic technology to produce high-value pharmaceutical proteins and bulk enzymes in the leaves of potato plants as well as other species, under greenhouse conditions.

Transgenic technology, using either animals or plants as bioreactors, addresses two major issues in the manufacture of biopharmaceuticals. The first...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

UCB Follows Fellow European Pharmas With Major US Investment

13 Jun 2025

• By Kevin Grogan

The Belgian drugmaker is boosting its biologics capacity over the pond.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

12 Jun 2025

• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?

Sanofi Cements RSV Dominance As Merck & Co. Rival Awaits FDA D-Day

09 Jun 2025

• By Kevin Grogan

The French company will start shipping its blockbuster shortly to meet expected strong demand in the 2025–26 RSV season.

Loss Of Exclusivity Product Launches To Fuel Aurobindo’s FY26 Europe Growth

29 May 2025

• By Vibha Ravi

Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now

BIO Notebook: IPO Window Stays Shut, PRVs Need To Be A Priority, And Focusing On Gene Therapy Safety

17 Jun 2025

• By Mandy Jackson and Sarah Karlin-Smith

Highlights from day one of the BIO convention include advice for firms hoping to go public, a call for companies to push the US Congress on rare disease priority review vouchers, and updates on next-generation gene therapies.

Sarepta Market Dynamics For Elevidys Imperiled By Second Patient Death

16 Jun 2025

• By Joseph Haas

With two deaths in non-ambulatory DMD patients, Sarepta is attempting damage control and will ask the US FDA to advise, setting up a possible confrontation with CBER director Prasad.

Supernus Secures Sage With CVR-Supported Deal